The "cake" of innovative drug market is 4 trillion yuan, which Chinese pharmaceutical companies can't bite

Source: daily economic news 2016-11-03 only accounts for one sixth of the world's 4 trillion yuan innovation drug market On the one hand, there is a huge market demand to be met, on the other hand, there is a backlog of approval and lack of progress in research and development of innovative drugs In recent years, policies and capital have been actively promoted, but the research and development of new drugs has been criticized as "simple repetition", the research and development of new drugs in tumor and other fields have been "clustered", while the categories of children's drugs appear relatively cold In the field of pharmaceutical investment, it is almost normal for new drugs to sharpen their swords in 10 years, and innovative drugs have become a capital adventure game After the continuous inflow of capital, drug research and development is "not bad money", but the other side of the coin is the phenomenon of capital imbalance There are few investors in the early stage of research and development, and in the later stage of predictable new drug market, a large number of capital is pouring in The investment bubble will follow Some people in the industry say that proper bubbles may be beneficial to industry, but this also means that more organizations are going to invest in the trend The professionalism and order of capital become the voice of the industry At the eighth annual conference of Chinese pharmaceutical entrepreneurs and 2016 pharmaceutical industry innovation forum held at the end of October this year, regulators and a large number of well-known pharmaceutical enterprises set the most concerned issues on pharmaceutical innovation, and innovative drugs became the most hot topic The reporter of "daily economic news" interviewed many entrepreneurs and industry personages, trying to restore the real predicament and capital relationship of domestic innovative medicine industry The 4 trillion yuan cake of innovative medicine market is waiting for segmentation, but Chinese pharmaceutical companies are quite weak According to the three echelons of innovation contribution distribution of major pharmaceutical R & D countries in the world, China is still in the third echelon, and its contribution to global pharmaceutical innovation is less than 5% In addition, in the three fields of pharmaceutical innovation layout, from low-end lean imitation to middle-end incremental innovation to the original innovation at the top of the tower, the pharmaceutical innovation in China has not yet climbed to the top of the tower, and the "quality" of the current pharmaceutical innovation still needs to be improved, most of which are incremental innovation Wu Zhen, deputy director of the national health and Family Planning Commission and deputy director of the State Food and drug administration, also stressed at the eighth annual conference of Chinese pharmaceutical entrepreneurs and 2016 pharmaceutical industry innovation forum that the current concept of new drugs has been transformed from "Chinese type" to "global type", which means that the new drugs needed are not simply repeated generic drugs He Wei, member of the Standing Committee of the CPPCC National Committee, deputy secretary general and full-time vice chairman of the Central Committee of the Democratic Party of agriculture and industry, said that China's new drug innovation should not pinch the softest persimmon, but put the limited funds in the most important place "The accumulation of basic research is the soil for the industrialization of innovative drugs." Wang Xijuan, chairman of Kangchen pharmaceutical, told the daily economic news that there is no unified standard for innovative drugs, which requires painstaking "internal skill" and careful consideration The separation of R & D focus and key demand coincides with the "tuyere" of the vigorous development of innovative drug market, and the Chinese pharmaceutical industry, which is closely related to people's life, has "targeted" the development goal from a large pharmaceutical country to a powerful pharmaceutical country According to the report on building a sustainable pharmaceutical innovation ecosystem in China (hereinafter referred to as the report), in 2015, the world's innovative pharmaceutical market reached nearly 600 billion US dollars, which is about 4 trillion yuan converted into RMB It is worth mentioning that the R & D of innovative drugs is also playing an increasingly important role in Chinese medicine No matter the policies, talents and investment have a better driving role in innovative drugs The number of articles published in top journals by Chinese insiders and the number of international drug patent applications have increased rapidly However, China occupies less than US $10 billion in this market, among which 19 innovative products approved for IPO for the first time in China contribute less than US $500 million, and the sales of these products are all from the Chinese market The adjustment of new drug classification also points out the wind vane of innovation At the conference, Wu Zhen said that the new drug classification has adjusted the definition of new drugs The concept of new drugs has changed from the "China type" which was the first to be listed in China in the past to the "national type" which was the first to be listed in the world In fact, the reason for doing so is to propose a new concept - the new drugs we need are not "simple repetition" Instead, we should encourage everyone to take the road of innovation He Wei believes that at present, the biomedical industry also faces the problem of separation of research and development focus and key demand For example, although the tumor field is very important, there is an excessive "clustering" of research and development, while there is a lack of research and development of other drugs with high demand In addition, he noted that trends in biomedicine and current health needs sometimes diverge from each other According to LV Qiang, vice president of operation of cornerstone pharmaceutical, this is a necessary stage IT industry, electronic home appliance manufacturing industry, etc., all have such a process: first, everyone rushes in, then integrates and unites in the competition, and finally forms several giants It is inevitable that innovative drugs repeat declaration at this stage Don't pinch the softest persimmon It should be noted that there is a certain gap between China's innovative drugs on the market and the leading countries in terms of "quality" According to the above report, it is difficult to promote industrialization due to weak basic research The original research and development of new drugs on the market is insufficient (mostly progressive innovation), for example, most of the new drugs are currently in the improvement of known drug targets and mechanisms of action, and they have not yet entered the international market due to the lack of research and development capabilities At present, the number of Chinese artificial biomedicine sold to the United States and the European Union is almost zero, said Yu Dechao, an expert in the 1000 person plan and chairman of Cinda bio The main reasons for the backwardness of China's biomedical industry are the lack of independent innovation, poor quality, small scale and high cost At the same time, some enterprises are more inclined to the research and development of generic drugs To this end, Liao Huaxin, an expert in the thousand talents program and chairman of Zhuhai tenor Mabo biology, told the daily economic news that from the current policy requirements, the gap between generic drugs and innovative drugs in terms of economic cost is not large The bottleneck of enterprise R & D of innovative drugs is still due to the lack of technology, and innovation must be based on deep basic research "The accumulation of basic research is the soil for the industrialization of innovative drugs." Wang Xijuan told the daily economic news that generic drugs use speed to win, but there is no unified standard for innovative drugs, which need to be carefully considered by themselves Because of the uncertainty of new drug research and development and the problem of cost performance, many pharmaceutical companies are reluctant to make innovative drugs Sun he, vice president of Tianshili group, said that at present, most of the domestic targets are found overseas first, and then the research is based on this, which is to hope to produce products quickly but lack of essential research, which is one of the difficulties of basic research He Wei stressed that China's new drug innovation should be "difficult, isolated and preventive", not "pinch the softest persimmon", and put the limited funds in the most important place.